

# Global Antidepressant Drugs Market Forecast up to 2018 – 2024

<https://marketpublishers.com/r/G09E801B58DEN.html>

Date: October 2018

Pages: 104

Price: US\$ 2,750.00 (Single User License)

ID: G09E801B58DEN

## Abstracts

Global Antidepressant Drugs Market – Drivers, Restraints, Opportunities, Trends, and Forecast: 2018–2024

Overview: Depression is a serious mental illness affecting more than 350 million people globally. This is also known as “major depression disorder” or “unipolar depression”. According to a report by the Psychiatric Association, nearly 14.8 million adults in the US are suffering from depression. Growing aging population and increasing prevalence of depression are the primary factors driving the global antidepressant drugs market growth. Supportive initiatives from the government & other organizations and increasing clinical trials will provide an opportunity for the market growth in the future.

At the global level, over 300 million people are estimated to suffer from depression, which is equivalent to 4.4% of the world’s total population. Only less than 10% of the affected people are treated although there is the availability of branded and effective treatments for depression. The challenges for effective care include lack of capitals, unavailability of qualified health-care providers, and public stigma associated with mental disorders. Along with these, imprecise assessment of the condition is also a challenge faced globally.

Market Analysis: The “global antidepressant drugs market” is estimated to witness a CAGR of 2.2% during the forecast period 2018–2024. The global antidepressant drugs market is analyzed based on drug class and regions.

Regional Analysis: The regions covered in the report are North America, Europe, Asia Pacific, and Rest of the World (ROW). North America accounts for the largest share of the antidepressant drugs market, followed by Europe, Asia Pacific, and Rest of the

World. North America alone occupies more than 30% of the market, with a significant contribution from the US to the market growth.

**Drug Class Analysis:** Based on the drug class, the market is segmented into selective serotonin reuptake inhibitors (SSRIs), norepinephrine–dopamine reuptake inhibitors (NDRI), serotonin and norepinephrine reuptake inhibitors (SNRIs), monoamine oxidase inhibitors (MAOIs), tricyclic antidepressants (TCAs), and others. SSRIs are the most attractive drug in the market, owing to the highly effective treatment of depression and anxiety.

**Key Players:** Novartis AG, Allergan Inc., Eli Lilly and Company, AstraZeneca plc, GSK, Otsuka Holdings Co., Ltd., and Johnson & Johnson are the key players in the market. The other prominent players include Pfizer, Shionogi & Co. Ltd., Abbott Laboratories, Takeda Pharmaceutical Co., Ltd., and H. Lundbeck A/S.

**Competitive Analysis:** Government initiatives have been greatly changing the market scenario. Many initiatives are taken to increase the awareness and reduce the suicidal rate globally. Depression is confined by the mental health Gap Action Programme (mhGAP) of the World Health Organization (WHO) to assist countries to increase their facilities for those suffering from mental disorders, through special aid by healthcare workers. A special transitory is established by WHO for the treatment of depression. The companies are striving to develop innovative drugs to address the unmet needs in the market. For instance, in May 2018, Esketamine Nasal Spray of the Janssen Pharmaceutical Companies of Johnson & Johnson demonstrated rapid enhancements in depressive symptoms in patients with treatment-resistant depression in Phase III trials. Thus, this drug is expected to be one of the bestsellers in the market.

**Benefits:** The report provides complete details about the usage and adoption rate of antidepressant drugs in various regions. With that, key stakeholders can know about the major trends, drivers, investments, and vertical player's initiatives. Moreover, the report provides details about the major challenges that are going to impact on the market growth. Additionally, the report gives the complete details about the key business opportunities to key stakeholders to expand their business and capture the revenue in the specific verticals to analyze before investing or expanding the business in this market.

## Contents

### **1 INDUSTRY OUTLOOK**

- 1.1 Industry Overview
- 1.2 Industry Trends
- 1.3 Total Addressable Market

### **2 REPORT OUTLINE**

- 2.1 Report Scope
- 2.2 Report Summary
- 2.3 Research Methodology
- 2.4 Report Assumptions

### **3 MARKET SNAPSHOT**

- 3.1 Market Definition – Infoholic Research
- 3.2 Segmented Addressable Market
  - 3.2.1 Trends in the Antidepressant Drugs Market
- 3.3 Related Markets
  - 3.3.1 Neurosurgical Devices
  - 3.3.2 Parkinson Drugs
    - 3.3.2.1 Trends of Parkinson Diseases Market
  - 3.3.3 Neurointerventional Devices
  - 3.3.4 Over the Counter Drugs (OTC)

### **4 MARKET OUTLINE**

- 4.1 Antidepressant Drugs Pipeline
- 4.2 Market Segmentation
- 4.3 Porter 5(Five) Forces
- 4.4 PEST Analysis

### **5 MARKET CHARACTERISTICS**

- 5.1 Market Dynamics
  - 5.1.1 Drivers
    - 5.1.1.1 Increasing aging population

- 5.1.1.2 Increasing prevalence of Depression
- 5.1.2 Opportunities
  - 5.1.2.1 Government Initiatives
  - 5.1.2.2 Exhaustive Pipeline and Increasing Clinical Trials
- 5.1.3 Restraints
  - 5.1.3.1 Complex drug development process
  - 5.1.3.2 Adverse effects of antidepressant drugs
- 5.2 DRO – Impact Analysis
- 5.3 Key Stakeholders

## **6 DRUG CLASS: MARKET SIZE AND ANALYSIS**

- 6.1 Overview
- 6.2 Selective serotonin reuptake inhibitors (SSRIs)
- 6.3 Norepinephrine-dopamine reuptake inhibitor (NDRI)
- 6.4 Serotonin and norepinephrine reuptake inhibitors (SNRIs)
- 6.5 Monoamine oxidase inhibitors (MAOIs)
- 6.6 Tricyclic antidepressants (TCAs)
- 6.7 Others

## **7 REGIONS: MARKET SIZE AND ANALYSIS**

- 7.1 Overview
- 7.2 North America
  - 7.2.1 Overview
- 7.3 Europe
  - 7.3.1 Overview
- 7.4 Asia Pacific
  - 7.4.1 Overview
- 7.5 Rest of the World
  - 7.5.1 Overview

## **8 COMPETITIVE LANDSCAPE**

## **9 VENDOR PROFILES**

- 9.1 AstraZeneca PLC
  - 9.1.1 Overview
  - 9.1.2 Business Units

- 9.1.3 Geographic Presence
- 9.1.4 Business Focus
- 9.1.5 SWOT Analysis
- 9.1.6 Business Strategies
- 9.2 Eli Lilly & Company Ltd.
  - 9.2.1 Overview
  - 9.2.2 Business Units
  - 9.2.3 Geographic Revenue
  - 9.2.4 Business Focus
  - 9.2.5 SWOT Analysis
  - 9.2.6 Business Strategies
- 9.3 GlaxoSmithKline plc
  - 9.3.1 Overview
  - 9.3.2 Business Units
  - 9.3.3 Geographic Presence
  - 9.3.4 Business Focus
  - 9.3.5 SWOT Analysis
  - 9.3.6 Business Strategies
- 9.4 Johnson & Johnson
  - 9.4.1 Overview
  - 9.4.2 Business Units
  - 9.4.3 Geographic Revenue
  - 9.4.4 Business Focus
  - 9.4.5 SWOT Analysis
  - 9.4.6 Business Strategies
- 9.5 Novartis AG
  - 9.5.1 Overview
  - 9.5.2 Business Units
  - 9.5.3 Geographic Presence
  - 9.5.4 Business Focus
  - 9.5.5 SWOT Analysis
  - 9.5.6 Business Strategy
- 9.6 Otsuka Holdings Co., Ltd.
  - 9.6.1 Overview
  - 9.6.2 Business Units
  - 9.6.3 Geographic Revenue
  - 9.6.4 Business Focus
  - 9.6.5 SWOT Analysis
  - 9.6.6 Business Strategies

## 9.7 Allergan PLC

### 9.7.1 Overview

### 9.7.2 Business Units

### 9.7.3 Geographic Revenue

### 9.7.4 Business Focus

### 9.7.5 SWOT Analysis

### 9.7.6 Business Strategies

## **10 COMPANIES TO WATCH FOR**

### 10.1 Pfizer, Inc.

#### 10.1.1 Overview

#### 10.1.2 Highlights

### 10.2 Takeda Pharmaceutical Co. Ltd.

#### 10.2.1 Overview

#### 10.2.2 Highlights

### 10.3 Shionogi & Co. Ltd.

#### 10.3.1 Overview

#### 10.3.2 Highlights

### 10.4 Abbott Laboratories

#### 10.4.1 Overview

### 10.5 H. Lundbeck A/S

#### 10.5.1 Overview

### Annexure

### Abbreviations

## List Of Tables

### LIST OF TABLES

TABLE 1 ASTRAZENECA PLC: OFFERINGS

TABLE 2 ASTRAZENECA PLC: RECENT DEVELOPMENTS

TABLE 3 ELI LILLY & COMPANY LTD.: PRODUCT OFFERINGS

TABLE 4 ELI LILLY & COMPANY LTD.: RECENT DEVELOPMENTS

TABLE 5 GLAXOSMITHKLINE PLC: OFFERINGS

TABLE 6 GLAXOSMITHKLINE PLC: RECENT DEVELOPMENTS

TABLE 7 JOHNSON & JOHNSON: PRODUCT OFFERINGS

TABLE 8 JOHNSON & JOHNSON: RECENT DEVELOPMENTS

TABLE 9 NOVARTIS AG: OFFERINGS

TABLE 10 NOVARTIS AG: RECENT DEVELOPMENTS

TABLE 11 TAKEDA PHARMACEUTICAL CO. LTD.: OVERVIEW

TABLE 12 TAKEDA PHARMACEUTICAL CO. LTD.: RECENT DEVELOPMENTS

TABLE 13 SHIONOGI & CO., LTD.: OVERVIEW

TABLE 14 SHIONOGI & CO., LTD.: RECENT DEVELOPMENTS

## List Of Charts

### LIST OF CHARTS

CHART 1 RESEARCH METHODOLOGY OF GLOBAL ANTIDEPRESSANT DRUGS MARKET

CHART 2 GLOBAL ANTIDEPRESSANT DRUGS MARKET REVENUE, 2017-2024 (\$MILLION)

CHART 3 CLINICAL TRIALS OF NEUROINTERVENTIONAL DEVICES

CHART 4 ANTIDEPRESSANT DRUGS PIPELINE

CHART 5 SEGMENTATION OF GLOBAL ANTIDEPRESSANT DRUGS MARKET

CHART 6 PORTER 5 FORCES OF ANTIDEPRESSANT DRUGS MARKET

CHART 7 PEST ANALYSIS OF ANTIDEPRESSANT DRUGS MARKET

CHART 8 MARKET DYNAMICS – DRO ANALYSIS

CHART 9 WORLD POPULATION AGED 65 YEARS AND ABOVE, 1960–2060 (%)

CHART 10 DRO – IMPACT ANALYSIS OF GLOBAL ANTIDEPRESSANT DRUGS MARKET

CHART 11 KEY STAKEHOLDERS

CHART 12 ANTIDEPRESSANT DRUGS MARKET BY DRUG TYPE SEGMENTATION, 2017-2024 (\$MILLION)

CHART 13 ANTIDEPRESSANT DRUGS MARKET REVENUE BY PRODUCTS TYPE, 2017–2024 (\$MILLION)

CHART 14 SELECTIVE SEROTONIN REUPTAKE INHIBITORS (SSRIS) DRUGS MARKET BY TYPES SEGMENTATION, 2017-2024 (\$MILLION)

CHART 15 NOREPINEPHRINE-DOPAMINE REUPTAKE INHIBITOR (NDRI) MARKET BY TYPES SEGMENTATION, 2017-2024 (\$MILLION)

CHART 16 SEROTONIN AND NOREPINEPHRINE REUPTAKE INHIBITORS (SNRIS) DRUGS MARKET BY TYPES SEGMENTATION, 2017-2024 (\$MILLION)

CHART 17 MONOAMINE OXIDASE INHIBITORS (MAOIS) DRUGS MARKET BY TYPES SEGMENTATION, 2017-2024 (\$MILLION)

CHART 18 TRICYCLIC ANTIDEPRESSANTS (TCAS) DRUGS MARKET BY TYPES SEGMENTATION, 2017-2024 (\$MILLION)

CHART 19 OTHERS ANTIDEPRESSANT DRUGS MARKET BY TYPES SEGMENTATION, 2017-2024 (\$MILLION)

CHART 20 CASES OF DEPRESSIVE DISORDER (MILLIONS), BY WHO REGION IN 2017 (%)

CHART 21 ANTIDEPRESSANT DRUGS MARKET BY REGIONAL SEGMENTATION, 2017 VS 2024 (%)

CHART 22 ANTIDEPRESSANT DRUGS MARKET REVENUE BY REGIONS,



2017–2024 (\$MILLION)

CHART 23 ANTIDEPRESSANT DRUGS MARKET REVENUE IN NORTH AMERICA,  
2017-2024 (\$MILLION)

CHART 24 PREVALENCE OF CHRONIC DEPRESSION, 2014

CHART 25 ANTIDEPRESSANT DRUGS MARKET REVENUE IN EUROPE, 2017–2024  
(\$MILLION)

CHART 26 ANTIDEPRESSANT DRUGS MARKET REVENUE IN ASIA PACIFIC,  
2017–2024 (\$MILLION)

CHART 27 ANTIDEPRESSANT DRUGS MARKET REVENUE IN REST OF THE  
WORLD, 2017–2024 (\$MILLION)

CHART 28 ASTRAZENECA PLC: OVERVIEW SNAPSHOT

CHART 29 ASTRAZENECA PLC: BUSINESS UNITS

CHART 30 ASTRAZENECA PLC: GEOGRAPHIC PRESENCE

CHART 31 ASTRAZENECA PLC: SWOT ANALYSIS

CHART 32 ELI LILLY & COMPANY LTD.: OVERVIEW SNAPSHOT

CHART 33 ELI LILLY & COMPANY LTD.: BUSINESS UNITS

CHART 34 ELI LILLY & COMPANY LTD.: GEOGRAPHIC REVENUE

CHART 35 ELI LILLY & COMPANY LTD.: SWOT ANALYSIS

CHART 36 GLAXOSMITHKLINE PLC: OVERVIEW SNAPSHOT

CHART 37 GLAXOSMITHKLINE PLC: BUSINESS UNITS

CHART 38 GLAXOSMITHKLINE PLC: GEOGRAPHIC PRESENCE

CHART 39 GLAXOSMITHKLINE PLC: SWOT ANALYSIS

CHART 40 JOHNSON & JOHNSON: OVERVIEW SNAPSHOT

CHART 41 JOHNSON & JOHNSON: BUSINESS UNITS

CHART 42 JOHNSON & JOHNSON: GEOGRAPHIC REVENUE

CHART 43 JOHNSON & JOHNSON: SWOT ANALYSIS

CHART 44 NOVARTIS AG: OVERVIEW SNAPSHOT

CHART 45 NOVARTIS AG: BUSINESS UNITS

CHART 46 NOVARTIS AG: GEOGRAPHICAL PRESENCE

CHART 47 NOVARTIS AG: SWOT ANALYSIS

CHART 48 OTSUKA HOLDINGS CO., LTD.: OFFERINGS

CHART 49 OTSUKA HOLDINGS CO., LTD.: RECENT DEVELOPMENTS

CHART 50 OTSUKA HOLDINGS CO., LTD.: OVERVIEW SNAPSHOT

CHART 51 OTSUKA HOLDINGS CO., LTD.: SEGMENTATION

CHART 52 OTSUKA HOLDINGS CO., LTD.: GEOGRAPHIC REVENUE

CHART 53 OTSUKA HOLDINGS CO., LTD.: SWOT ANALYSIS

CHART 54 ALLERGAN PLC: OFFERINGS

CHART 55 ALLERGAN PLC: RECENT DEVELOPMENTS

CHART 56 ALLERGAN PLC: OVERVIEW SNAPSHOT

CHART 57 ALLERGAN PLC: BUSINESS UNITS  
CHART 58 ALLERGAN PLC: GEOGRAPHIC REVENUE  
CHART 59 ALLERGAN PLC: SWOT ANALYSIS  
CHART 60 PFIZER, INC.: RECENT DEVELOPMENTS  
CHART 61 PFIZER, INC: KEY DEVELOPMENTS  
CHART 62 ABBOTT LABORATORIES: RECENT DEVELOPMENTS  
CHART 63 ABBOTT LABORATORIES: KEY DEVELOPMENTS  
CHART 64 H. LUNDBECK A/S: OVERVIEW  
CHART 65 H. LUNDBECK A/S: RECENT DEVELOPMENTS

## I would like to order

Product name: Global Antidepressant Drugs Market Forecast up to 2018 – 2024

Product link: <https://marketpublishers.com/r/G09E801B58DEN.html>

Price: US\$ 2,750.00 (Single User License / Electronic Delivery)

If you want to order Corporate License or Hard Copy, please, contact our Customer Service:

[info@marketpublishers.com](mailto:info@marketpublishers.com)

## Payment

To pay by Credit Card (Visa, MasterCard, American Express, PayPal), please, click button on product page <https://marketpublishers.com/r/G09E801B58DEN.html>

To pay by Wire Transfer, please, fill in your contact details in the form below:

First name:  
Last name:  
Email:  
Company:  
Address:  
City:  
Zip code:  
Country:  
Tel:  
Fax:  
Your message:

**\*\*All fields are required**

Customer signature \_\_\_\_\_

Please, note that by ordering from marketpublishers.com you are agreeing to our Terms & Conditions at <https://marketpublishers.com/docs/terms.html>

To place an order via fax simply print this form, fill in the information below and fax the completed form to +44 20 7900 3970